The impact of LABA+ICS fixed combinations on morbidity and economic burden of COPD in Italy: A six-year observational study

Therapeutic Advances in Respiratory Disease

Volumn 5, Issue 2, 2011, Pages 83-90

  Dal Negro, Roberto ^a   Bonadiman, Luca ^b   Tognella, Silvia ^a   Micheletto, Claudio ^a   Turco, Paola ^c  

^a Ospedale 2   (Italy)

^b CESFAR Centro Studi Nazionale FISAR di Farmaco Economia e Farmaco Epidemiologia Respiratoria   (Italy)

^c Centro Nazionale Studi di Farmacoeconomia e Farmacoepidemiologia Respiratoria   (Italy)

Author keywords

COPD; inhaled steroids; LABA; LABA ICS fixed combinations; outcomes; pharmacoeconomics; therapeutic impact

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LONG ACTING BETA 2 AGONIST; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; ECONOMIC ASPECT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OBSERVATIONAL STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SPIROMETRY; TREATMENT FAILURE;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; DRUG THERAPY, COMBINATION; ECONOMICS, PHARMACEUTICAL; FEMALE; HEALTH EXPENDITURES; HEALTH RESOURCES; HUMANS; ITALY; MALE; MIDDLE AGED; MORBIDITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 79953299895     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465810386052     Document Type: Article

References (15)

1. Almagro P. Salvadó M. Garcia-Vidal C. Rodriguez-Carballeira M. Delgado M. Barreiro B. (2010) Recent improvement in long-term survival after a COPD hospitalization. Thorax 65: 298–302.
2. Calverley P.M.A. Anderson J.A. Celli B. Ferguson G.T. Jenkins C. Jones P.W. (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775–789.
3. Calverley P.M.A. Pauwels R. Vesto J. Jones P. Pride N. Gulsvik A. for the TRISTAN study group. Combining salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet (2003) 361: 449–456.
4. Chan-Yeung M. Ait-Khaled N. White N. Tsang K.W. Tan W.C. (2004) The burden and impact of COPD in Asia and Africa. Int J Tuberc Lung Dis 8: 1–14.
5. Chapman K.R. Mannino D.M. Soriano J.B. Vermeire P.A. Buist A.S. Thun M.J. (2006) Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 27: 188–207.
6. Dal Negro R. Berto P. Tognella S. Quareni L. (2002) Cost of illness of lung disease in the TriVeneto Region, Italy: the GOLD Study. Monaldi Arch Chest Dis 57: 1–7.
7. Dal Negro R.W. Eandi M. Pradelli L. Iannazzo S. (2007a) Cost-effectiveness and health care budget impact in Italy of Inhaled corticosteroids and brochodilators for severe and very severe COPD patients. Int J COPD 2: 1–8.
8. Dal Negro R.W. Tognella S. Tosatto R. Dionisi M. Turco P. Donner C.F. (2008) Costs of chronic obstructive pulmonary disease (COPD) in Italy: The SIRIO study (Social Impact of Respiratory Integrated Outcomes). Respir Med 102: 92–101.
9. Kardos P. Wencker M. Glaab T. Vogelmeier C. (2007) Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 144–149.
10. Mahler D.A. Wire P. Horstman D. Chang C.N. Yates J. Fischer T. (2002) Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166: 1084–1091.
11. Miravitlles M. Murio C. Guerrero T. Gisbert R. for the DAFNE Study Group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest (2002) 121: 1449–1455.
12. Murray C.J. Lopez A.D. (1997) Alternative projections of mortality and disability by cause 1990–2020 ’ Global Burden of Disease Study. Lancet 349: 1498–1504.
13. Nishimura S. Zaher C. (2004) Cost impact of COPD in Japan: opportunities and challenges? Respirology 9: 466–473.
14. Rennard S. Decramer M. Calverley P.M.A. Calverley P.M. Pride N.B. Soriano J.B. (2000) Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur Respir J 20: 799–805.
15. Wouters E.F. Postma D.S. Fokkens B. Hop W.C. Prins J. Kuipers A.F. (2005) Withdrawal of fluticasone propionate from combined fluticasone/salmeterol treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 60: 480–487.